Immunooncology: Genmab teams up with Immat...Danish Genmab and German Immatics Biotechnologies are collaborating to discover and develop next-generation bispecific immunotherapies to develop therapeutics in multiple cancer indications. more ➔
Big Data: Tracking cancer risk genesUsing only openly available genomic data, researchers in Barcelona have developed a new method to systematically identify genes contributing to heritable cancer risk. more ➔
Lifecare floats on Oslo stock exchangeNorwegian diabetes expert Lifecare AS has gone public on the Oslo stock exchange. The sensor maker plans to fund the next phase of development for its implantable glucose sensor. more ➔
Abingworth closes new biotech fund at €2...Bioscience investment firm Abingworth has closed its latest fund at US$315m (€268m). The money will go to life sciences companies in Europe and the US. more ➔
€47m for rare disease biotechAfter €7m went to Nextbiotix last week, another financing round is bringing money to a young French biotech. Strasbourg-based Dynacure attracted €47m from investors to bring its lead candidate for … more ➔
€7m for French microbiome start-upMicrobiome start-up Nextbiotix raised € 7m in a Series A round. The Paris-based biotech uses commensal bacteria as drugs to treat major inflammatory bowel diseases. more ➔
Highs and lows for Fresenius Medical CareDialysis product and service provider Fresenius Medical Care has placed €500m notes. Yesterday, the medtech giant had to come to terms with a sharp drop in share price. more ➔
Chemspec Europe 2018 in Cologne closes wit... The 33rd edition of Chemspec Europe, International Exhibition for Fine and Speciality Chemicals, ended after two successful show days with record visitor numbers. From 20 to 21 June 2018, a total of … more ➔
Piglet vaccination to reduce antibiotics u...Researchers at VTT Technical Research Centre of Finland have developed a vaccine, diluted into drinking water, to treat diarrhoea on piglets being weaned. The vaccine is expected to reduce the global … more ➔
VarmX raises €12.5mVarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from … more ➔
